Oncology
Feature
Walking intensity and step count are linked to health benefits
In a large study, researchers examined how fast individuals moved and parsed the benefits of “incidental” versus “purposeful” steps.
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.
From the Journals
BRAF/MEK combo shows long-term efficacy in melanoma
Despite positive results, immunotherapy likely remains the best choice for first-line treatment of BRAFV600 mutated advanced melanoma.
Conference Coverage
New ESC guidelines for cutting CV risk in noncardiac surgery
The guidelines, which aim to reduce cardiovascular complications from noncardiac surgery, introduce new concepts and recommendations, compared...
From the Journals
Annual screening benefits people at high-risk for pancreatic cancer
Opponents of screening suggested while screening may identify cancer earlier, it doesn’t necessarily improve outcomes.
Conference Coverage
Not just what, but when: Neoadjuvant pembrolizumab in melanoma
Neoadjuvant pembrolizumab followed by pembrolizumab improves event-free survival in resectable melanoma.
Conference Coverage
Could nivolumab prevent oral cancer in high-risk patients?
Immunotherapy as a preventative strategy, as first-line or secondary, should be further explored.
Conference Coverage
Novel cell therapy beats immunotherapy in melanoma
The treatment of patients with melanoma who do not respond to or progress after receiving immunotherapy is “challenging and represents an unmet...
Conference Coverage
‘Unprecedented’ responses to neoadjuvant treatment in dMMR colon cancer
Neoadjuvant immunotherapy “has the potential to become standard of care” in these patients.
Conference Coverage
Pembro/chemo combo fails to improve event-free survival in head and neck cancer
Some trends favored chemoradiation plus pembrolizumab over chemoradiation alone, but KEYNOTE-412 failed to meet primary endpoint.
Conference Coverage
In NSCLC, not all EGFR mutations are the same
Patients with the Ex20 insertion may buck trend by responding well to ICIs.